SCHEMBL5640633

SCHEMBL5640633

O=CN[C@H]1CCCCN(C(=O)NC2CCCC2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.45
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ADH1B P00325 2/20 0.38
ADH1C P00326 2/20 0.38
ADH1A P07327 2/20 0.38
ADH7 P40394 1/20 0.38
POLB P06746 3/20 0.37
HSD17B10 Q99714 1/20 0.37
ADH4 P08319 1/20 0.37
LMNA P02545 3/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5638198 0.99 HTT (0.44) HTTTSHRSMN1; SMN2NPC1RAB9A
SCHEMBL5638050 0.99 HTT (0.47) HTTTSHRSMN1; SMN2NPC1RAB9A
SCHEMBL5640787 0.97 HTT (0.41) HTTTSHRSMN1; SMN2NPC1RAB9A
SCHEMBL5637029 0.84 POLB (0.35) ADH1BADH1CADH1AADH7POLB
SCHEMBL5637709 0.84 POLB (0.35) ADH1BADH1CADH1AADH7POLB
SCHEMBL5638791 0.82 XIAP (0.33) SMN1; SMN2
SCHEMBL5637448 0.81 ADH1B (0.33) SMN1; SMN2ADH1BADH1CADH1AADH7
SCHEMBL5638209 0.81 ADH1B (0.33) SMN1; SMN2ADH1BADH1CADH1AADH7
SCHEMBL5639094 0.81 LMNA (0.36) SMN1; SMN2LMNAALDH1A1
SCHEMBL5640627 0.80 HTT (0.45) HTTTSHRSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 US disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 HTT 4237/4885TSHR 667/4885SMN1; SMN2 4121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.